Abstract
Approximately 250,000 people are diagnosed with breast cancer and 40,000 people die from the disease annually in the United States. Significant effort has been put into developing a thorough understanding of the molecular and genetic events that contribute to tumor progression due to mounting evidence that breast cancers are driven by predictable and identifiable genetic mutations, Sphingolipids modulate many of the growth, apoptosis, inflammatory, and angiogenic pathways that breast carcinomas rely on. Recent work in the field of sphingolipidomics has identified many key roles for the sphingolipids in breast tumor progression and identified signaling roles in each of the molecular subtypes of breast cancer. For example, in luminal type tumors, increased expression of ceramide producing enzymes and high levels of complex sphingolipids are associated with poor outcomes and multi-drug resistance. In basal type breast tumors CERT and GCS play a role in resistance to taxanes suggesting that targeting these pathways may be an effective route for the treatment of aggressive triple negative tumors. The role of sphingolipids in Her2-like tumors has not been thoroughly studied. However, CERK has been identified as potential driver of Her2-like tumors. Clearly, sphingolipid signaling in tumor modulation is both complex and vital. By integrating sphingolipid signaling into the molecular characterization of breast tumors, new opportunities for targeted intervention are identified. It is increasingly apparent that modulating sphingolipid levels in tumors will be an effective and powerful method for the treatment of breast cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
American Cancer Society (2013) Cancer facts & figures 2013. American Cancer Society, Atlanta
Hajdu SI (2011) A note from history: landmarks in history of cancer, part 1. Cancer 117(5):1097–1102
Vargas A et al (2012) [The Edwin Smith papyrus in the history of medicine]. Rev Med Chil 140(10):1357–1362
Aszmann OC (2000) The life and work of Theodore Schwann. J Reconstr Microsurg 16(4):291–295
Triolo VA (1965) Nineteenth century foundations of cancer research advances in tumor pathology, nomenclature, and theories of oncogenesis. Cancer Res 25:75–106
Hajdu SI, Darvishian F (2013) A note from history: landmarks in history of cancer, part 5. Cancer 119(8):1450–1466
Hajdu SI (2012) A note from history: landmarks in history of cancer, part 4. Cancer 118(20):4914–4928
Sistrunk WE, Maccarty WC (1922) Life expectancy following radical amputation for carcinoma of the breast: a clinical and pathologic study of 218 cases. Ann Surg 75(1):61–69
Hajdu SI, Vadmal M (2013) A note from history: Landmarks in history of cancer, Part 6. Cancer 119(23):4058–4082
Beatson G (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 148(3803):162–165
Love RR, Philips J (2002) Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 94(19):1433–1434
Rous P (1911) A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 13(4):397–411
DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643–8653
Umeda M, Heidelberger C (1968) Comparative studies of fluorinated pyrimidines with various cell lines. Cancer Res 28(12):2529–2538
Oshaughnessy JA et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12(9):1247–1254
Kunimoto T, Hori M, Umezawa H (1967) Modes of action of phleomycin, bleomycin and formycin on HeLa S3 cells in synchronized culture. J Antibiot (Tokyo) 20(5):277–281
Di Marco A, Gaetani M, Scarpinato B (1969) Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep 53(1):33–37
Creasey WA et al (1976) Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Res 36(1):216–221
Moore FD et al (1967) Carcinoma of the breast. A decade of new results with old concepts. N Engl J Med 277(7):343–350
Jensen EV (1975) Estrogen receptors in hormone-dependent breast cancers. Cancer Res 35(11 Pt. 2):3362–3364
Block GE et al (1978) Correlation of estrophilin content of primary mammary cancer to eventual endocrine treatment. Ann Surg 188(3):372–376
Ward HW (1973) Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1(5844):13–14
Slichenmyer WJ, Von Hoff DD (1991) Taxol: a new and effective anti-cancer drug. Anticancer Drugs 2(6):519–530
Hanauske AR et al (1992) Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3(2):121–124
Seidman AD et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649
Sparano JA et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671
Druker BJ et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561–566
Pegram M et al (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18(13):2241–2251
Pegram MD, Konecny G, Slamon DJ (2000) The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103:57–75
Baselga J et al (2001) Mechanism of action of trastuzumab and scientific update. Semin Oncol 28(5 Suppl 16):4–11
Hardy NM, Fowler DH, Bishop MR (2006) Immunotherapy of metastatic breast cancer: phase I trail of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange. Clin Breast Cancer 7(1):87–89
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York, p 649
Schott A (2014) Systemic treatment of metastatic breast cancer in women: Chemotherapy
Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752
Howlader N et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5):pii: dju055
Sørlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98(19):10869–10874
Parker JS et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167
Voduc KD et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684–1691
Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70
Hannun YA, Obeid LM (2002) The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 277(29):25847–25850
Snyder RA, Brady RO, Kornblith PL (1970) Ganglioside patterns of cultured human glioma cells. Neurology 20(4):412
Keenan TW et al (1975) Exogenous glycosphingolipids suppress growth rate of transformed and untransformed 3 T3 mouse cells. Exp Cell Res 92(2):259–270
Manuelidis L, Yu RK, Manuelidis EE (1977) Ganglioside content and pattern in human gliomas in culture. Correlation of morphological changes with altered gangliosides. Acta Neuropathol 38(2):129–135
Bremer EG, Schlessinger J, Hakomori S (1986) Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor. J Biol Chem 261(5):2434–2440
Okada Y, Matsuura H, Hakomori S (1985) Inhibition of tumor cell growth by aggregation of a tumor-associated glycolipid antigen: a close functional association between gangliotriaosylceramide and transferrin receptor in mouse lymphoma L-5178Y. Cancer Res 45(6):2793–2801
Kim YS et al (1986) Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res 46(11):5985–5992
Hannun YA, Bell RM (1989) Regulation of protein kinase C by sphingosine and lysosphingolipids. Clin Chim Acta 185(3):333–345
Chen Z et al (2014) Protein kinase C-delta inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo. BMC Cancer 14:90
Kim J et al (2011) Sustained inhibition of PKCalpha reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene 30(3):323–333
Chalfant CE et al (1999) Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem 274(29):20313–20317
Hanada K et al (2003) Molecular machinery for non-vesicular trafficking of ceramide. Nature 426(6968):803–809
Charruyer A et al (2008) Decreased ceramide transport protein (CERT) function alters sphingomyelin production following UVB irradiation. J Biol Chem 283(24):16682–16692
Blom T et al (2012) Tracking sphingosine metabolism and transport in sphingolipidoses: NPC1 deficiency as a test case. Traffic 13(9):1234–1243
Fyrst H, Saba JD (2010) An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 6(7):489–497
Bertucci F et al (2005) Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 65(6):2170–2178
Prat A et al (2013) Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 142(2):237–255
Schnitt SJ (2010) Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 23(S2):S60–S64
Bange J, Zwick E, Ullrich A (2001) Molecular targets for breast cancer therapy and prevention. Nat Med 7(5):548–552
Stemke-Hale K et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084–6091
Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9(8):537–549
Tran B, Bedard PL (2011) Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 13(6):221
Wirapati P et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65
Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790–800
Troester MA et al (2006) Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 6:276
Jiang Z et al (2010) Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest 120(9):3296–3309
Neve RM et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–527
Ruckhaberle E et al (2009) Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. J Cancer Res Clin Oncol 135(1):81–90
Zhang X et al (2012) Doxorubicin influences the expression of glucosylceramide synthase in invasive ductal breast cancer. PLoS One 7(11), e48492
Lucki NC, Sewer MB (2011) Genistein stimulates MCF-7 breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression. J Biol Chem 286(22):19399–19409
Bai A et al (2009) Synthesis and bioevaluation of omega-N-amino analogs of B13. Bioorg Med Chem 17(5):1840–1848
Ruckhaberle E et al (2009) Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer. Climacteric 12(6):502–513
Ruckhaberle E et al (2008) Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112(1):41–52
Liu YY et al (2011) Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma. Int J Oncol 39(2):425–431
Sun YL et al (2005) [Construction of glucosylceramide synthase-specific siRNA expression vector and its efficiency in reversal of drug resistance in breast carcinoma cells]. Zhonghua Yi Xue Za Zhi 85(8):518–521
Gouaze V et al (2005) Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 65(9):3861–3867
Lavie Y et al (1997) Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272(3):1682–1687
Bose R et al (1995) Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82(3):405–414
Lucci A et al (1999) Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 86(2):300–311
Charles AG et al (2001) Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 47(5):444–450
Gewirtz DA (2000) Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Res Treat 62(3):223–235
Schiffmann S et al (2009) Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 30(5):745–752
Erez-Roman R, Pienik R, Futerman AH (2010) Increased ceramide synthase 2 and 6 mRNA levels in breast cancer tissues and correlation with sphingosine kinase expression. Biochem Biophys Res Commun 391(1):219–223
Hartmann D et al (2012) Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int J Biochem Cell Biol 44(4):620–628
Walker T et al (2009) Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol 76(2):342–355
Min J et al (2007) (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol Cancer Res 5(8):801–812
Hoeferlin LA et al (2013) Folate stress induces apoptosis via p53-dependent de novo ceramide synthesis and up-regulation of ceramide synthase 6. J Biol Chem 288(18):12880–12890
Bareford MD et al (2012) Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biol Ther 13(9):793–803
Wooten-Blanks LG et al (2007) Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1. FASEB J 21(12):3386–3397
Koybasi S et al (2004) Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem 279(43):44311–44319
Demircan B et al (2009) Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer 48(1):83–97
Chalmers IJ et al (2001) Mapping the chromosome 16 cadherin gene cluster to a minimal deleted region in ductal breast cancer. Cancer Genet Cytogenet 126(1):39–44
Vijayaraghavalu S et al (2012) Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. Mol Pharm 9(9):2730–2742
Ito H et al (2009) Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta 1789(11-12):681–690
Ellegaard AM et al (2013) Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol Cancer Ther 12(10):2018–2030
Zeidan YH, Jenkins RW, Hannun YA (2008) Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J Cell Biol 181(2):335–350
Canals D et al (2010) Differential effects of ceramide and sphingosine 1-phosphate on ERM phosphorylation: probing sphingolipid signaling at the outer plasma membrane. J Biol Chem 285(42):32476–32485
Perry DM et al (2014) Defining a role for acid sphingomyelinase in the p38/interleukin-6 pathway. J Biol Chem 10(6):515–527
Ullio C et al (2012) Sphingosine mediates TNFalpha-induced lysosomal membrane permeabilization and ensuing programmed cell death in hepatoma cells. J Lipid Res 53(6):1134–1143
Bhabak KP et al (2013) Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues. Bioorg Med Chem 21(4):874–882
Jenkins RW et al (2011) Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase. J Biol Chem 286(15):13292–13303
Cain BS et al (1999) Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 27(7):1309–1318
Mathias S et al (1993) Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. Science 259(5094):519–522
Hannun YA (1994) The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269(5):3125–3128
Zeidan YH et al (2006) Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-{alpha}-induced PGE2 production. J Biol Chem 281(34):24695–24703
Chen D et al (2007) Prostaglandin E(2) induces breast cancer related aromatase promoters via activation of p38 and c-Jun NH(2)-terminal kinase in adipose fibroblasts. Cancer Res 67(18):8914–8922
Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267(2):271–285
Pinilla S et al (2009) Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett 284(1):80–85
Zhang Y et al (2009) Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 21(4):1113–1121
Karczewska A et al (2000) Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer 88(9):2061–2071
Salgado R et al (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103(5):642–646
Dethlefsen C, Hojfeldt G, Hojman P (2013) The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138(3):657–664
Asgeirsson KS et al (1998) The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 10(9):720–728
Watson C et al (2010) High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 177(5):2205–2215
Zhang Y et al (2014) Sphingosine kinase 1 and cancer: a systematic review and meta-analysis. PLoS One 9(2), e90362
Pinho FG et al (2013) Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation. Cancer Res 73(19):5936–5948
Takabe K et al (2010) Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem 285(14):10477–10486
Kim ES et al (2014) Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBPbeta and potentiates breast cancer progression. Oncogene 33(27):3583–3593
Rutherford C et al (2013) Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. Cell Death Dis 4, e927
Hu X et al (2009) Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 7(4):511–522
Gustin DJ et al (2013) Structure guided design of a series of sphingosine kinase (SphK) inhibitors. Bioorg Med Chem Lett 23(16):4608–4616
Rex K et al (2013) Sphingosine kinase activity is not required for tumor cell viability. PLoS One 8(7), e68328
Ruckhaberle E et al (2009) Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol 135(8):1005–1013
Pastukhov O et al (2014) The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death. Br J Pharmacol 171(24):5829–5844
Chandriani S et al (2009) A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One 4(8), e6693
Liedtke C et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281
Stover T, Kester M (2003) Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther 307(2):468–475
Shabbits JA, Mayer LD (2003) Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta 1612(1):98–106
Stover TC et al (2005) Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 11(9):3465–3474
Miyaji M et al (2005) Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med 202(2):249–259
Watters RJ et al (2012) Development and use of ceramide nanoliposomes in cancer. Methods Enzymol 508:89–108
Tran MA et al (2008) Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 14(11):3571–3581
Wilhelm SM et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129–3140
Tan QX et al (2014) Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials. Exp Ther Med 7(5):1420–1426
Pedersen AM et al (2014) Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor alpha. Int J Oncol 45(5):2167–2175
Pedrosa LR et al (2013) Improving intracellular doxorubicin delivery through nanoliposomes equipped with selective tumor cell membrane permeabilizing short-chain sphingolipids. Pharm Res 30(7):1883–1895
Zolnik BS et al (2008) Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos 36(8):1709–1715
Sirohi B et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19(11):1847–1852
Swanton C et al (2007) Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11(6):498–512
Juul N et al (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11(4):358–365
Hla T et al (2000) Sphingosine-1-phosphate signaling via the EDG-1 family of G-protein-coupled receptors. Ann N Y Acad Sci 905:16–24
Mousseau Y et al (2012) Fingolimod inhibits PDGF-B-induced migration of vascular smooth muscle cell by down-regulating the S1PR1/S1PR3 pathway. Biochimie 94(12):2523–2531
Long JS et al (2010) Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J Biol Chem 285(46):35957–35966
Nagaoka Y et al (2008) Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Biol Pharm Bull 31(6):1177–1181
Azuma H et al (2002) Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 62(5):1410–1419
Slamon D et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283
Joensuu H et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809–820
Goss PE et al (2013) Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14(1):88–96
Goldhirsch A et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028
Agrawal A et al (2005) Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 12(Suppl 1):S135–S144
Lee AJ et al (2012) CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J Pathol 226(3):482–494
Payne AW et al (2014) Ceramide kinase promotes tumor cell survival and mammary tumor recurrence. Cancer Res 74(21):6352–6363
Kim IC et al (2013) Lipid profiles for HER2-positive breast cancer. Anticancer Res 33(6):2467–2472
Sano O et al (2007) Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1. J Lipid Res 48(11):2377–2384
Montefusco DJ et al (2013) Distinct signaling roles of ceramide species in yeast revealed through systematic perturbation and systems biology analyses. Sci Signal 6(299):p. rs14
Acknowledgements
The authors would like to acknowledge the SUNY Stony Brook Bioinformatics Facility. The results presented in Fig. 1 are based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This work is partly supported by NCI grant P01 CA097132. We thank Dr. Christopher J. Clarke for careful review of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Newcomb, B., Hannun, Y.A. (2015). Sphingolipids as Mediators of Breast Cancer Progression, Metastasis, Response and Resistance to Chemotherapy. In: Hannun, Y., Luberto, C., Mao, C., Obeid, L. (eds) Bioactive Sphingolipids in Cancer Biology and Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-20750-6_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-20750-6_4
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-20749-0
Online ISBN: 978-3-319-20750-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)